RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19

In the study (n=14,892), there was no evidence that aspirin 150 mg daily reduced mortality vs usual care (28 day mortality of 17% for both arms). The results were consistent across all pre-specified subgroups of patients.

Source:

Oxford University